Trial Profile
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Entinostat (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.
- 01 Aug 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2024.
- 01 Aug 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.